Study objective: To evaluate a population based screening programme for breast cancer. Design: This was a case-control study of women dying of breast cancer between 1977 and 1987 who had been invited to take part in a screening programme. Setting: Community based study of women aged between 40 and 70 years (total population about 35 000 at 1981 census), living in 23 small towns near Florence, Italy. Participants: 103 cases were identified from death certification, and 515 living controls (five per case) selected for year of birth and town of residence. Measurements and main results: Screening history was obtained from computer archive. Sociodemographic information was obtained from town registry offices and directly from relatives of the deceased and from the controls by postal questionnaire, and if necessary telephone or personal interview. Analysis was carried out on two age groups-40-49 years and 50 + years at diagnosisand considered the number of screening tests and the time interval since the last test, separately and together. In the older age group, women with at least one screening test in the previous 2j years showed a 50% reduction in risk (odds ratio 0-49, 95% confidence interval . If they had also had another previous negative screen the risk was reduced to one third (odds ratio 0-35, 95% CI 0-14-0-85). There was a significant trend of decreasing risk with increasing number of screens in older women. No clear evidence of a similar protective effect was shown for women in the 40-49 year age group. Conclusions: A significant protective effect of the screening programme is evident in older women but not in younger ones. The data do not allow an assessment ofoptimal screening interval because of the small number of previously screened cases. 
A screening programme for the early diagnosis of breast cancer, currently under way in the Province of Florence and involving the female population aged between 40 and 70, was started in 1970, immediately after the preliminary results of the HIP randomised study in New York.' Since then it has progressively involved 23 municipalities around Florence. These are grouped under three USLs (local health authorities), and are mostly located in the hill or mountain areas which are particularly disadvantaged with regard to access to breast diagnostic facilities. In four other small towns, the programme was stopped in the early 1970s because of organisational problems.
The programme is run by a centre located in Florence (Centre for the Study and Prevention of Oncological diseases: CSPO) which runs other cancer screening programmes as well in cooperation with the local health authorities.
Screening is based on a single first level test-double view mammography. The whole resident female population in the age group 40-70 years (33 075 women at the last national census in 1981) is invited by mail using the registry lists provided from time to time by the individual town councils. Invitations to undergo mammography are currently issued about every two years, though previously the interval was longer. On average, in the period [1970] [1971] [1972] [1973] [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] , the interval between two succeeding invitations has been around 30 months.
Mammographies are carried out in two mobile units 242 (specially equipped vans), in which the mammographs are installed. These self driven units, moving from town to town, are operated by radiographers provided by CSPO and by experienced nurses from the local health authority. A form is filled for each participating woman, so that clinical and demographic information can be collected. The development and interpretation ofthe radiograms are carried out at the CSPO centre in Florence.
Physical examination is reserved for cases selected on the basis of symptoms (with the exception of pain alone) or radiological signs. The physical examination and any other necessary diagnostic test (in particular radiological examinations, or cytology of nipple discharge or fine needle aspirate) are always carried out in the CSPO breast clinic.
The results of a first case-control study, carried out by us and published recently,2 showed a significant protective effect of the programme for women over 50 years. In younger women, within the age group 40-49 years, there was no such evidence ofa protective effect. Briefly, the methodology chosen was that of a casecontrol study design, as in other European studies;3 4 the cases were defined as women who had died of breast cancer, who were resident in the screening area and who were first diagnosed after the start of the programme itself (after at least the first invitation). The study considered 57 women who died in the period 1977-84 in the two USLs (11 and 18) and for whom registered information on the death certificates was available at that time.
The public health planning implications of the published results have prompted the updating of the study to include cases relating to the years 1985-87, and the enlargement of the area studied to include all 23 municipalities currently participating in the programme. The collection of information about a set of additional variables, considered as potential confounders, was planned in order to make the analysis more reliable.
The larger sample size of the study has also allowed us to consider in more depth the definition of the "exposure" (participation in the programme) not only in quantitative terms (number of mammographies) but also in relation to temporal factors (interval since last examination). These factors may be important for several reasons. For example in a situation where subjects may have been screened as long ago as 10 or more years before the valid date, a simple analysis of the type "women never screened/women screened at least once" could be insufficient. The same type of analysis performed according to the number of mammographies undergone could be potentially confounded by the fact that the time interval since last test for subjects who have undergone a greater number of examinations tends to be shorter than for subjects Domenico Palli, et al who have undergone only one examination. The low relative risk, shown in the previous study, for women over 50 with at least two mammographies (as compared with only one) could simply have been due to the fact that they had undergone the last examination more recently.
In the 23 towns included in the present study the time interval between the start of the programme and the end of the period considered varies from a minimum of 6 years up to a maximum of 17 years. Nineteen cases were recorded as screen detected: eight in the 40-49 age group (four at a first test and four at a repeat test) and 11 in the older group (six at a first test and five at a repeat test).
Methods

CONTROLS
Five living women were identified for each case. They were matched strictly according to town of residence and year of birth. The screening history information for each woman was collected from the computerised archives at CSPO, while other demographic data were found at the town registry offices, the aim being to reduce comparability problems arising from interviews involving surviving relatives of cases opposed to the women themselves in the control group. Overall 515 women were identified and considered as controls.
The mammographic examinations carried out on them within the screening programme were considered only up until the diagnosis date of the case with whom they were matched.
SOURCE OF INFORMATION
For each subject the information about the screening history until the date of diagnosis of the case in each matched set was collected from the computerised archives available at CSPO.
Time interval since last test in a breast cancer screening programme: a case-control study in Italy Despite problems of comparability already mentioned, it was decided to investigate further the role of potential confounding variables by collecting additional information through a self administered postal questionnaire. A prepaid envelope was enclosed and a reminder with another copy ofthe questionnaire was sent if there was no reply after 4 weeks. For all the cases the questionnaire was sent to the last known address. The surviving relatives of the cases and the living controls were contacted by telephone or personally at their address when no answer was received. Overall the compliance to the questionnaire (by mail, telephone or interview) was over 98%.
The variables considered in the questionnaire were selected according to their potential role as confounders and for their ability to confirm correct reporting by the relatives: number of children, age at first birth, occupation of the woman, occupation of the spouse, level of education, family history of breast cancer (mother and/or sister).
Other information was collected from the computerised archive available at CSPO for cervical cytology and mammographies performed outside the screening programme, at the self referral Florence breast clinic.
ANALYSIS
In the analyses of all the data in this study, we considered separately the number of examinations carried out and the time interval since the last test, and we also considered these two aspects together (categorised as follows: "number of examinations", 1 or 2+; "interval since last test", below or above 30 months, that is the average period between two succeeding rounds).
The interval of 30 months was calculated backward from the exact date ofdiagnosis for each case (and her matched controls); screen detected cases therefore fall into the "screened less than 30 months before" category, together with interval cases diagnosed in the first 21 years following a test. Only clinically detected cases with a last screening test more than 30 months before the diagnosis fall in the other category.
The analysis was carried out with a conditional logistic model, utilising the PHGLM procedure in the "SAS" statistical package5 and the IBM 3083 mainframe available at the Regional Tuscany Council. Crude odds ratios (conditional logistic model without confounding variables) and adjusted odds ratios with their 95% confidence intervals (CI) were estimated and presented in the tables. Only adjusted odds ratios are presented in the results section and considered in the discussion. Potential confounding variables were categorised as follows:
Number of children: 0, A simple dichotomous analysis of ever versus never screened women reveals, as expected, a protective effect of screening, although the effect is weaker in the 40-49 year age group (table 2) . Overall, considering the two age groups together, the adjusted odds ratio is 0-53 (95% CI 0 33-0-85).
After considering the number of screening tests, the estimates presented in table 3 show, in the older age group, a reduction in risk of about 40% (odds ratio 0-62, 95% CI 0-32-1-19) for women screened only once; this reduction in risk reaches 60% for those screened at least twice (odds ratio 0-40, 95% CI 0 19-0 82). A significant trend of decreasing risk with an increasing number of screening tests was present (p=00-1).
In the 4049 year age group the results do not show this trend: for women screened at least twice the relative risk is greater than 1 (odds ratio 1 18, 95% CI 0-31X4-47). 
Discussion
Adjustment for several potential confounders, on the basis of the information collected following a rigid protocol (a first postal questionnaire, a reminder after a few weeks, telephone contacts or a final personal interview) did not substantially affect the estimates of the protective effect of screening participation. The differences between crude and adjusted odds ratios in this analysis were always very small. The present results, in agreement with our previous study, do not show any significant evidence of a protective effect for younger women attending the programme, even after considering the interval since the last test and the total number oftests performed. A first explanation (apart from the small number of women in this age group) could be the lower sensitivity of mammography in the younger women, probably due to the higher "density" of breast tissues.6
It is also possible, however, that the interval between two screening rounds in this programme (2-3 years, 30 months on the average) is too long to produce any protective effect for screened women in the age group under 50 years. The Swedish "two county" randomised trial recently estimated that in this age group the incidence rate in the second year after a screening test is already 70% of the rate observed in the control group.7
The results of another Swedish study, the randomised trial in Malmo8 showed no effect in women younger than 55 years of age. Also the UK trial, in which women in the 45-64 age group were invited, showed only a slight protective effect, about 20% reduction in risk across all ages, falling short of statistical significance;9 no age specific data were available.
The average time interval between the start of the programme and the end of the period considered in this study (December 1987 ) is rather long and a longer latency of the appearance of the protective effect in this younger group, as suggested by the HIP study,'0 seems an unlikely explanation.
Our results according to the analysis "ever versus never screened" show a significant protective effect, overall and in the older age group. However such a simple approach is unsatisfactory, in particular when the follow up becomes very long. After considering the number of screening tests, it is shown that older women screened at least twice are significantly protected; a trend ofdecreasing risk with an increasing number of tests is evident. It is clear, however, that temporal factors should also be taken into account.
In the older age group, the women examined in the previous 30 months showed a risk ofdying from breast cancer in the following years which was significantly lower than in never screened women. This reduction in risk was more evident for those women with at least one other previous screening test. These results suggest an independent effect of both the "interval since last test" and of the "number of tests" carried out in the programme (only one/two or more).
According to the analysis presented in table 6, the major issue is the difference between the protective effect ofa first single test and that ofa repeat screening test (all women with two or more tests are considered together in this category): the two categories could actually be defined as women with a "prevalence" screen and women with a "repeat" screen in the last 30 months. 
